Updated Aug 12, 2026
/RBC Bearings pays $24.2 million cash for PSC Couplings through Dodge Industrial subsidiary/Phase 3 clascoterone results point to novel mechanism in male hair loss, Spokane dermatologist says/Spruce Power stockholders vote to adjourn 2026 annual meeting to August 25/Google Pixel Buds 2a drop to $99 at Amazon, Best Buy and Google's own store/Intel holds above 100-day moving average after AI-linked capital raise/Manus to return as independent company after China forces Meta to unwind $2 billion deal/RBC Bearings pays $24.2 million cash for PSC Couplings through Dodge Industrial subsidiary/Phase 3 clascoterone results point to novel mechanism in male hair loss, Spokane dermatologist says/Spruce Power stockholders vote to adjourn 2026 annual meeting to August 25/Google Pixel Buds 2a drop to $99 at Amazon, Best Buy and Google's own store/Intel holds above 100-day moving average after AI-linked capital raise/Manus to return as independent company after China forces Meta to unwind $2 billion deal
NewsSOS
← NewswireEarnings

Phase 3 clascoterone results point to novel mechanism in male hair loss, Spokane dermatologist says

SPOKANE, Wash., Aug. 11. Phase 3 results for clascoterone 5% topical solution, an investigational treatment for male androgenetic alopecia, are drawing attention across dermatology, according to a Globe Newswire release issued Monday. Spokane dermatologist Dr. Wm. Philip Werschler said the findings support a novel mechanism for the condition.

By Jonah Berg2 min read
Share

Key takeaways

  • Phase 3 results for clascoterone 5% topical solution, an investigational treatment for male androgenetic alopecia, are drawing attention across dermatology, according to a Globe Newswire release issued Monday, Aug. 11.
  • Spokane dermatologist Dr. Wm. Philip Werschler said the findings support a novel mechanism for male hair loss.
  • Phase 3 is the final required clinical testing stage before a drug sponsor can apply for regulatory approval, and clascoterone 5% topical solution carries investigational status.
  • The available portion of the release did not identify specific enrollment figures, primary endpoints, or the sponsoring company.
  • The text did not specify what distinguishes this mechanism from existing treatment pathways or include regulatory filing timelines.

SPOKANE, Wash., Aug. 11. Phase 3 results for clascoterone 5% topical solution, an investigational treatment for male androgenetic alopecia, are drawing attention across dermatology, according to a Globe Newswire release issued Monday. Spokane dermatologist Dr. Wm. Philip Werschler said the findings support a novel mechanism for the condition.

What the data indicate

Phase 3 marks the final required clinical testing stage before a drug sponsor can apply for regulatory approval. Clascoterone 5% topical solution carries investigational status, the release confirms. Dr. Werschler's commentary centered on the mechanistic implications of the trial findings. Specific enrollment figures, primary endpoints, and the sponsoring company were not identified in the available portion of the release.

Why the findings drew attention

The release attributed dermatology's attention directly to the mechanistic finding: the Phase 3 data point toward what Dr. Werschler characterized as a novel mechanism for male hair loss. Dr. Wm. Philip Werschler, a Spokane, Washington dermatologist, addressed what the release described as the significance of the results. The available text did not specify what distinguishes this mechanism from existing treatment pathways or include regulatory filing timelines.

Note: The source release was available only in truncated form. This report reflects the facts present in the headline and disclosed summary text. No figures, trial identifiers, or company names appeared in the available excerpt.

Keep reading

All bulletins →
EarningsAugust 11, 2026

Treasury guidance would allow pre-tax payroll contributions to Trump Accounts

WASHINGTON, Aug. 11. The U.S. Department of Treasury issued guidance that could allow parents to make pre-tax contributions to a child's Trump Account directly from their paycheck, the department said. Employers could match those…

2 min read
EarningsAugust 11, 2026

Lilly's Foundayo wins U.K. approval, first for weight-loss pill outside United States

LONDON, Aug. 11. Eli Lilly's weight-loss pill Foundayo has received regulatory approval in the United Kingdom, the drug's first clearance outside the United States. The decision carries Lilly's competition with Novo Nordisk's Wegovy beyond…

2 min read
EarningsAugust 11, 2026

Trump Media posts $238 million Q2 loss as cryptocurrency positions fall

NEW YORK, Aug. 11. Trump Media & Technology Group reported a second-quarter net loss of $238.1 million, up from roughly $20 million in the same period a year earlier, with unrealized losses on its cryptocurrency holdings driving most of…

2 min read

Frequently asked

What is clascoterone 5% topical solution being studied for?

It is an investigational treatment for male androgenetic alopecia (male hair loss).

Why did the Phase 3 findings draw attention?

The release attributed dermatology's attention to the mechanistic finding, with the data pointing toward what Dr. Werschler characterized as a novel mechanism for male hair loss.

Who commented on the results?

Dr. Wm. Philip Werschler, a dermatologist in Spokane, Washington, addressed the significance of the results.

Does Phase 3 mean the drug is approved?

No; Phase 3 is the final required testing stage before a sponsor can apply for regulatory approval, and the solution still carries investigational status.

What details were missing from the release?

The available excerpt did not include enrollment figures, primary endpoints, trial identifiers, the sponsoring company, or regulatory filing timelines.